Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 43 (5) , 341-348
Abstract
Objective: To evaluate the effects of multiple doses of omeprazole and of a single dose of an aluminium hydroxide/magnesium hydroxide (Al/Mg) antacid on the single-dose plasma pharmacokinetics of lumiracoxib. Study Design: Open-label, randomised, three-period, crossover study. Population Studied: Healthy subjects aged 18–65 years. Methods: Fourteen subjects who met eligibility criteria were each administered three treatments in random order: (A) lumiracoxib 400mg as a single oral dose; (B) oral omeprazole 20mg once daily for 4 consecutive days, then lumiracoxib 400mg as a single oral dose just prior to oral omeprazole 20mg on day 5; and (C) lumiracoxib 400mg as a single oral dose immediately prior to a 20mL dose of Al/Mg antacid (magnesium hydroxide 800mg and aluminium hydroxide 900mg). The interval between each lumiracoxib dose was 7 days. Analysis of variance was performed to determine whether lumiracoxib alone differed from lumiracoxib plus omeprazole or from lumiracoxib plus Al/Mg antacid for overall exposure (area under the concentration-time curve from zero to infinity [AUC∞]) and peak concentration (Cmax), with treatment sequence, subject, period and treatment as factors. Ratios of geometric means between lumiracoxib plus omeprazole and lumiracoxib plus Al/Mg antacid to lumiracoxib alone (reference) were calculated for AUC∞ and Cmax. If the mean ratios, with 90% CIs, fell within the interval 0.80–1.25, the treatments were considered equivalent. Results: Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching Cmax values (mean ± SD) of 9.24 ± 1.96, 8.81 ± 2.30, and 10.43 ± 3.24 mg/L within 2–3 hours for treatments A, B and C, respectively. AUC∞ was similar for the three treatments (36.75 ± 7.73, 34.88 ± 8.40 and 35.50 ± 5.72 mg • h/L). All ratios of geometric means with 90% CIs fell within the interval used for establishing bioequivalence, except for the Cmax comparison between lumiracoxib plus Al/Mg antacid and lumiracoxib alone, which was 1.11 (0.95, 1.31). Conclusion: Coadministration of lumiracoxib with omeprazole or with an Al/Mg antacid had no clinically significant effect on lumiracoxib single-dose plasma pharmacokinetics. Lumiracoxib can, therefore, be administered concurrently with either of these agents without need for lumiracoxib dosage alteration.Keywords
This publication has 20 references indexed in Scilit:
- Low Frequency of Upper Gastrointestinal Complications in a Cohort of High-Risk Patients Taking Low-Dose Aspirin or NSAIDS and OmeprazoleScandinavian Journal of Gastroenterology, 2003
- Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with ArthritisNew England Journal of Medicine, 2002
- Is hirudin a potential therapeutic agent for arthritis?Annals of the Rheumatic Diseases, 2002
- Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazoleXenobiotica, 2001
- COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacinGut, 2000
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- World Medical Association Declaration of HelsinkiJAMA, 1997
- Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be uselessGastroenterology, 1996
- OmeprazoleDrugs, 1994
- The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac.British Journal of Clinical Pharmacology, 1991